



# WJG

## World Journal of Gastroenterology®

**Indexed and Abstracted in:**

Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®) and Journal Citation Reports/Science Edition, *Index Medicus*, MEDLINE and PubMed, Chemical Abstracts, EMBASE/Excerpta Medica, Abstracts Journals, *Nature Clinical Practice Gastroenterology and Hepatology*, CAB Abstracts and Global Health.  
ISI JCR 2003-2000 IF: 3.318, 2.532, 1.445 and 0.993.

**Volume 15 Number 17**  
**May 7, 2009**

*World J Gastroenterol*  
2009 May 7; 15(17): 2049-2176

**Online Submissions**

[wjg.wjgnet.com](http://wjg.wjgnet.com)

[www.wjgnet.com](http://www.wjgnet.com)

Printed on Acid-free Paper

世界胃肠病学杂志



# World Journal of Gastroenterology®

Weekly Established in October 1995

Volume 15 Number 17  
May 7, 2009



## Contents

- |                          |      |  |
|--------------------------|------|--|
| <b>EDITORIAL</b>         | 2049 | Intrahepatic cholestasis of pregnancy<br><i>Geenes V, Williamson C</i>   |
|                          | 2067 | Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease<br><i>Hoentjen F, van Bodegraven AA</i>   |
| <b>TOPIC HIGHLIGHT</b>   | 2074 | Clinical applications of hepatocyte transplantation<br><i>Pietrosi G, Vizzini GB, Gruttadauria S, Gridelli B</i>   |
| <b>OBSERVATION</b>       | 2078 | <i>Tropheryma whipplei</i> infection<br><i>Freeman HJ</i>  |
| <b>REVIEW</b>            | 2081 | Importance of nutrition in inflammatory bowel disease<br><i>Lucendo AJ, De Rezende LC</i>  |
| <b>ORIGINAL ARTICLES</b> | 2089 | High <i>miR-196a</i> levels promote the oncogenic phenotype of colorectal cancer cells<br><i>Schimanski CC, Frerichs K, Rahman F, Berger M, Lang H, Galle PR, Moehler M, Gockel I</i>  |
|                          | 2097 | Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation<br><i>Renga B, Mencarelli A, Migliorati M, Distrutti E, Fiorucci S</i>   |
|                          | 2109 | Involvement of 90-kuD ribosomal S6 kinase in collagen type I expression in rat hepatic fibrosis<br><i>Yang MF, Xie J, Gu XY, Zhang XH, Davey AK, Zhang SJ, Wang JP, Zhu RM</i>   |
|                          | 2116 | Components of the mitogen-activated protein kinase cascade are activated in hepatic cells by <i>Echinococcus multilocularis</i> metacestode<br><i>Lin RY, Wang JH, Lu XM, Zhou XT, Mantion G, Wen H, Vuitton DA, Richert L</i> |
|                          | 2125 | C-type natriuretic-peptide-potentiated relaxation response of gastric smooth muscle in streptozotocin-induced diabetic rats<br><i>Cai YL, Xu DY, Li XL, Qiu ZX, Jin Z, Xu WX</i>   |

**BRIEF ARTICLES**

- 2132 Hyperferritinemia is a risk factor for steatosis in chronic liver disease  
*Licata A, Nebbia ME, Cabibbo G, Lo Iacono G, Barbaria F, Brucato V, Alessi N, Porrovecchio S, Di Marco V, Craxì A, Cammà C*
- 2139 Evaluation of a rabbit rectal VX2 carcinoma model using computed tomography and magnetic resonance imaging  
*Liang XM, Tang GY, Cheng YS, Zhou B*
- 2145 Clinicopathological significance of B-cell-specific Moloney murine leukemia virus insertion site 1 expression in gastric carcinoma and its precancerous lesion  
*Zhao J, Luo XD, Da CL, Xin Y*
- 2151 Efficacy of  $\beta$ -adrenergic blocker plus 5-isosorbide mononitrate and endoscopic band ligation for prophylaxis of esophageal variceal rebleeding: A meta-analysis  
*Ding SH, Liu J, Wang JP*

**CASE REPORT**

- 2156 Unusual presentations of eosinophilic gastroenteritis: Case series and review of literature  
*Sheikh RA, Prindiville TP, Pecha RE, Ruebner BH*
- 2162 Endoscopic submucosal dissection of a rectal carcinoid tumor using grasping type scissors forceps  
*Akahoshi K, Motomura Y, Kubokawa M, Matsui N, Oda M, Okamoto R, Endo S, Higuchi N, Kashiwabara Y, Oya M, Akahane H, Akiba H*
- 2166 Lansoprazole-associated collagenous colitis: Diffuse mucosal cloudiness mimicking ulcerative colitis  
*Chiba M, Sugawara T, Tozawa H, Tsuda H, Abe T, Tokairin T, Ono I, Ushiyama E*

**LETTERS TO THE EDITOR**

- 2170 Emerging clinical and therapeutic applications of *Nigella sativa* in gastroenterology  
*Kapoor S*

**ACKNOWLEDGMENTS**

- 2172 Acknowledgments to reviewers of *World Journal of Gastroenterology*

**APPENDIX**

- 2173 Meetings
- 2174 Instructions to authors

**FLYLEAF**

- I-VII Editorial Board

**INSIDE BACK COVER**

Online Submissions

**INSIDE FRONT COVER**

Online Submissions

**INTRODUCTION**

*World Journal of Gastroenterology* is an international, open-access, peer-reviewed, and multi-disciplinary weekly journal that serves gastroenterologists and hepatologists. The biggest advantage of the open access model is that it provides free, full-text articles in PDF and other formats for experts and the public without registration, which eliminates the obstacle that traditional journals possess and usually delays the speed of the propagation and communication of scientific research results. The open access model has been proven to be a true approach that may achieve the ultimate goal of the journals, i.e. the maximization of the values of the readers, the authors and the society.

Maximization of the value of the readers can be comprehended in two ways. First, the journal publishes articles that can be directly read or downloaded free of charge at any time, which attracts more readers. Second, the readers can apply the knowledge in clinical practice without delay after reading and understanding the information in their fields. In addition, the readers are encouraged to propose new ideas based on those of the authors, or to provide viewpoints that are different from those of the authors. Such discussions or debates among different schools of thought will definitely boost advancements and developments in the fields. Maximization of the value of the authors refers to the fact that these journals provide a platform that promotes the speed of propagation and communication to a maximum extent. This is also what the authors really need. Maximization of the value of the society refers to the maximal extent of the social influences and impacts produced by the high quality original articles published in the journal. **This is also the main purpose of many journals around the world.**

**EDITORS FOR THIS ISSUE**

**Responsible Assistant Editor:** *Xiao-Fang Liu*  
**Responsible Electronic Editor:** *Xiao-Mei Zheng*  
**Proofing Editorial Office Director:** *Jian-Xia Cheng*

**Responsible Science Editor:** *Lin Tian*  
**Responsible Copy Editor:** *Catbel Kerr, PhD*  
**Proofing Editor-in-Chief:** *Lian-Sheng Ma*

<p><b>NAME OF JOURNAL</b> <i>World Journal of Gastroenterology</i></p> <p><b>RESPONSIBLE INSTITUTION</b> Department of Science and Technology of Shanxi Province</p> <p><b>SPONSOR</b> Taiyuan Research and Treatment Center for Digestive Diseases, 77 Shuangta Xijie, Taiyuan 030001, Shanxi Province, China</p> <p><b>EDITING</b> Editorial Board of <i>World Journal of Gastroenterology</i>, Room 903, Building D, Ocean International Center, No.62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China                  Telephone: +86-10-59080039                  Fax: +86-10-85381893                  E-mail: <a href="mailto:wjg@wjgnet.com">wjg@wjgnet.com</a>  <a href="http://www.wjgnet.com">http://www.wjgnet.com</a></p> <p><b>PUBLISHING</b> The WJG Press and Beijing Baishideng BioMed Scientific Co., Ltd., Room 903, Building D, Ocean International Center, No.62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China                  Telephone: +86-10-59080039                  Fax: +86-10-85381893                  E-mail: <a href="mailto:wjg@wjgnet.com">wjg@wjgnet.com</a>  <a href="http://www.wjgnet.com">http://www.wjgnet.com</a></p> <p><b>PRINTING</b> Beijing Kexin Printing House</p> <p><b>OVERSEAS DISTRIBUTOR</b> Beijing Bureau for Distribution of Newspapers and Journals (Code No. 82-261)                  China International Book Trading Corporation PO Box 399, Beijing, China (Code No. M4481)</p> <p><b>PUBLICATION DATE</b> May 7, 2009</p> <p><b>EDITOR-IN-CHIEF</b> Lian-Sheng Ma, <i>Beijing</i></p>	<p><b>SUBSCRIPTION</b> RMB 50 Yuan for each issue, RMB 2400 Yuan for one year</p> <p><b>CSSN</b> ISSN 1007-9327 CN 14-1219/R</p> <p><b>HONORARY EDITORS-IN-CHIEF</b> Montgomery Bissell, <i>San Francisco</i>                  James L Boyer, <i>New Haven</i>                  Chao-Long Chen, <i>Kaohsiung</i>                  Ke-Ji Chen, <i>Beijing</i>                  Li-Fang Chou, <i>Taipei</i>                  Jacques V Dam, <i>Stanford</i>                  Martin H Floch, <i>New Haven</i>                  Guadalupe Garcia-Tsao, <i>New Haven</i>                  Zhi-Qiang Huang, <i>Beijing</i>                  Shinn-Jang Hwang, <i>Taipei</i>                  Ira M Jacobson, <i>New York</i>                  Derek Jewell, <i>Oxford</i>                  Emmet B Keeffe, <i>Palo Alto</i>                  Min-Liang Kuo, <i>Taipei</i>                  Nicholas F LaRusso, <i>Rochester</i>                  Jie-Shou Li, <i>Nanjing</i>                  Geng-Tao Liu, <i>Beijing</i>                  Lein-Ray Mo, <i>Tainan</i>                  Bo-Rong Pan, <i>Xi'an</i>                  Fa-Zu Qiu, <i>Wuhan</i>                  Eamonn M Quigley, <i>Cork</i>                  David S Rampton, <i>London</i>                  Rafiq A Sheikh, <i>Sacramento</i>                  Rudi Schmid, <i>Kentfield</i><sup>1)</sup>                  Nicholas J Talley, <i>Rochester</i>                  Sun-Lung Tsai, <i>Yong-Kang City</i>                  Guido NJ Tytgat, <i>Amsterdam</i>                  Hsiu-Po Wang, <i>Taipei</i>                  Jaw-Ching Wu, <i>Taipei</i>                  Meng-Chao Wu, <i>Shanghai</i>                  Ming-Shiang Wu, <i>Taipei</i>                  Jia-Yu Xu, <i>Shanghai</i>                  Ta-Sen Yeh, <i>Taoyuan</i>                  Ming-Lung Yu, <i>Kaohsiung</i></p> <p><b>STRATEGY ASSOCIATE EDITORS-IN-CHIEF</b>                  Peter Draganov, <i>Florida</i>                  Ronnie Fass, <i>Tucson</i>                  Hugh J Freeman, <i>Vancouver</i>                  John P Geibel, <i>New Haven</i>                  Maria C Gutiérrez-Ruiz, <i>México</i></p>	<p>Kazuhiro Hanazaki, <i>Kochi</i>                  Akio Inui, <i>Kagoshima</i>                  Kalpesh Jani, <i>Vadodara</i>                  Sanaa M Kamal, <i>Cairo</i>                  Ioannis E Koutroubakis, <i>Heraklion</i>                  Jose JG Marin, <i>Salamanca</i>                  Javier S Martin, <i>Punta del Este</i>                  Natalia A Osna, <i>Omaha</i>                  Jose Sahel, <i>Marseille</i>                  Ned Snyder, <i>Galveston</i>                  Nathan Subramaniam, <i>Brisbane</i>                  Wei Tang, <i>Tokyo</i>                  Alan BR Thomson, <i>Edmonton</i>                  Paul Joseph Thuluvath, <i>Baltimore</i>                  James F Trotter, <i>Denver</i>                  Shingo Tsuji, <i>Osaka</i>                  Harry HX Xia, <i>Hanover</i>                  Yoshio Yamaoka, <i>Houston</i>                  Jesus K Yamamoto-Furusho, <i>México</i></p> <p><b>ASSOCIATE EDITORS-IN-CHIEF</b>                  Gianfranco D Alpini, <i>Temple</i>                  Bruno Annibale, <i>Roma</i>                  Roger William Chapman, <i>Oxford</i>                  Chi-Hin Cho, <i>Hong Kong</i>                  Alexander L Gerbes, <i>Munich</i>                  Shou-Dong Lee, <i>Taipei</i>                  Walter Edwin Longo, <i>New Haven</i>                  You-Yong Lu, <i>Beijing</i>                  Masao Omata, <i>Tokyo</i></p> <p><b>EDITORIAL OFFICE</b>                  Director: Jian-Xia Cheng, <i>Beijing</i>                  Deputy Director: Jian-Zhong Zhang, <i>Beijing</i></p> <p><b>LANGUAGE EDITORS</b>                  Director: Jing-Yun Ma, <i>Beijing</i>                  Deputy Director: Xian-Lin Wang, <i>Beijing</i></p> <p><b>MEMBERS</b>                  Gianfranco D Alpini, <i>Temple</i>                  BS Anand, <i>Houston</i>                  Manoj Kumar, <i>Nepal</i>                  Patricia F Lalor, <i>Birmingham</i>                  Ming Li, <i>New Orleans</i>                  Margaret Lutze, <i>Chicago</i>                  Sabine Mihm, <i>Göttingen</i>                  Francesco Negro, <i>Genève</i>                  Bernardino Rampone, <i>Siena</i>                  Richard A Rippe, <i>Chapel Hill</i>                  Stephen E Roberts, <i>Swansea</i></p>	<p><b>COPY EDITORS</b>                  Gianfranco D Alpini, <i>Temple</i>                  Sujit Kumar Bhattacharya, <i>Kolkata</i>                  Filip Braet, <i>Sydney</i>                  Kirsteen N Browning, <i>Baton Rouge</i>                  Radha K Dhiman, <i>Chandigarh</i>                  John Frank Di Mari, <i>Texas</i>                  Shannon S Glaser, <i>Temple</i>                  Eberhard Hildt, <i>Berlin</i>                  Patricia F Lalor, <i>Birmingham</i>                  Ming Li, <i>New Orleans</i>                  Margaret Lutze, <i>Chicago</i>                  MI Torrs, <i>Jaén</i>                  Sri Prakash Misra, <i>Allahabad</i>                  Bernardino Rampone, <i>Rome</i>                  Giovanni Monteleone, <i>Rome</i>                  Valerio Nobili, <i>Rome</i>                  Osman Cavit Ozdogan, <i>Istanbul</i>                  Francesco Perri, <i>San Giovanni Rotondo</i>                  Thierry Piche, <i>Nice</i>                  Bernardino Rampone, <i>Siena</i>                  Richard A Rippe, <i>Chapel Hill</i>                  Ross C Smith, <i>Sydney</i>                  Daniel Lindsay Worthley, <i>Bedford</i>                  George Y Wu, <i>Farmington</i>                  Jian Wu, <i>Sacramento</i></p> <p><b>COPYRIGHT</b>                  © 2009 Published by The WJG Press and Baishideng. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of WJG. Authors are required to grant WJG an exclusive licence to publish.</p> <p><b>SPECIAL STATEMENT</b>                  All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.</p> <p><b>INSTRUCTIONS TO AUTHORS</b>                  Full instructions are available online at <a href="http://www.wjgnet.com/wjg/help/instructions.jsp">http://www.wjgnet.com/wjg/help/instructions.jsp</a>. If you do not have web access please contact the editorial office.</p> <p><b>ONLINE SUBMISSION</b>  <a href="http://wjg.wjgnet.com">http://wjg.wjgnet.com</a></p>
---	---	---	--

BRIEF ARTICLES

## Hyperferritinemia is a risk factor for steatosis in chronic liver disease

Anna Licata, Maria Elena Nebbia, Giuseppe Cabibbo, Giovanna Lo Iacono, Francesco Barbaria, Virna Brucato, Nicola Alessi, Salvatore Porrovecchio, Vito Di Marco, Antonio Craxì, Calogero Cammà

Anna Licata, Maria Elena Nebbia, Giuseppe Cabibbo, Giovanna Lo Iacono, Francesco Barbaria, Virna Brucato, Nicola Alessi, Salvatore Porrovecchio, Vito Di Marco, Antonio Craxì, Calogero Cammà, Gastroenterology and Hepatology Unit, Department of Internal Medicine, University of Palermo, 90127 Palermo, Italy

**Author contributions:** Licata A and Cammà C contributed equally to this work; Licata A, Craxì A and Cammà C designed the research; Licata A, Nebbia ME, Cabibbo G, Lo Iacono G, Barbaria F, Brucato V, Alessi N, Porrovecchio S and Di Marco V performed the research; Cammà C analyzed the data; Licata A, Nebbia ME and Cammà C wrote the paper.

**Correspondence to:** Dr. Anna Licata, MD, Gastroenterology and Hepatology Unit, Department of Internal Medicine, University of Palermo, 90127 Palermo, Italy. [annalisalicata@yahoo.com](mailto:annalisalicata@yahoo.com)

Telephone: +39-91-6552145 Fax: +39-91-6552156

Received: July 6, 2008 Revised: April 3, 2009

Accepted: April 10, 2009

Published online: May 7, 2009

levels were significantly related to low platelet count, steatosis and hepatitis C virus infection.

**CONCLUSION:** In a non-obese cohort of non-alcoholic patients with chronically abnormal LFTs without HH, high serum ferritin level is a risk factor for steatosis.

© 2009 The WJG Press and Baishideng. All rights reserved.

**Key words:** Steatosis; Serum ferritin; Chronic liver disease; Hepatitis C;  $\gamma$ -glutamyltransferase

**Peer reviewer:** Michael Torbenson, MD, Associate Professor of Pathology, Room B314 1503 E Jefferson (Bond Street Building), The Johns Hopkins University School of Medicine, Baltimore, MD 21231, United States

Licata A, Nebbia ME, Cabibbo G, Lo Iacono G, Barbaria F, Brucato V, Alessi N, Porrovecchio S, Di Marco V, Craxì A, Cammà C. Hyperferritinemia is a risk factor for steatosis in chronic liver disease. *World J Gastroenterol* 2009; 15(17): 2132-2138 Available from: URL: <http://www.wjgnet.com/1007-9327/15/2132.asp> DOI: <http://dx.doi.org/10.3748/wjg.15.2132>

### Abstract

**AIM:** To investigate the relationship between ferritin and steatosis in patients with chronically abnormal liver function tests (LFTs) and high ferritin level.

**METHODS:** One hundred and twenty-four consecutive patients with hyperferritinemia (male > 300 ng/mL, female > 200 ng/mL) were evaluated; clinical, biochemical and serological data, iron status parameters, *HFE* gene mutations and homeostasis model assessment score were obtained. Steatosis was graded by ultrasound as absent or present. Histology was available in 53 patients only.

**RESULTS:** Mean level of ferritin was  $881 \pm 77$  ng/mL in men and  $549 \pm 82$  ng/mL in women. The diagnosis was chronic hepatitis C in 53 (42.7%), non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in 57 (45.9%), and cryptogenic liver damage in 14 (11.3%). None was diagnosed as hereditary hemochromatosis (HH). Hepatic siderosis on liver biopsy was present in 17 of 54 (32%) patients; grade 1 in eight and grade 2 in nine. Overall, 92 patients (74.2%) had steatosis. By logistic regression, ferritin and  $\gamma$ -glutamyltransferase were independent predictors of steatosis. Ferritin

### INTRODUCTION

There may be high serum ferritin levels in systemic inflammatory conditions and in renal, liver and neoplastic diseases<sup>[1,2]</sup>. Among patients with chronic liver disease, high serum ferritin, besides being a hallmark of hereditary hemochromatosis (HH), is frequently found in chronic hepatitis C, in alcoholic or non-alcoholic steatohepatitis (NASH), and in non-alcoholic fatty liver disease (NAFLD).

A raised ferritin level, with an increased transferrin saturation and liver iron concentration, is a typical presentation of HH, an autosomal recessive disorder linked to *HFE* gene mutations<sup>[3]</sup>, which account for most cases of HH in northern Europe and the USA<sup>[4]</sup>. Epidemiological studies in Mediterranean populations have shown that C282Y occurs only sporadically, while H63D is found among 13.5% of the general population<sup>[5]</sup>. In this area, *HFE* polymorphism seems to have a modest diagnostic relevance, since many cases of HH do not display the classic pattern of mutations<sup>[5]</sup>. It

has been suggested that *HFE* mutations may be involved in cases of liver disease complicated by iron overload and in patients with type 2 diabetes<sup>[6]</sup>.

Patients with chronic hepatitis C virus (HCV) infection often have elevated serum iron indices<sup>[7]</sup>, but these do not reflect accurately hepatic iron content, nor are they able to predict clinically important endpoints, such as progression of fibrosis and responsiveness to interferon-based regimens<sup>[8-10]</sup>. Studies attempting to link iron and the course of chronic hepatitis C have been inconclusive<sup>[11]</sup>. In chronic hepatitis C, steatosis is a common histological finding and occurs in 30%-70% of patients<sup>[12-13]</sup>. The biological mechanism underlying steatosis in HCV infection is not definitively understood and is considered to be multifactorial with metabolic mechanisms, including insulin resistance (IR)<sup>[14]</sup> and iron overload<sup>[8,11,15]</sup>. In fact, steatosis in patients infected by HCV genotype 1 is linked to a raised  $\gamma$ -glutamyltransferase (GGT) and to IR as a result of lipid peroxidation in the liver<sup>[14]</sup>. The high prevalence of diabetes in subjects chronically infected with HCV has been ascribed to an increase in IR mediated by an increase in iron deposits<sup>[16,17]</sup>.

In NAFLD, recent studies<sup>[18-20]</sup> have reported conflicting data on the role of iron in causing liver damage. George *et al.*<sup>[21]</sup> and Bonkovsky *et al.*<sup>[22]</sup> have shown that patients with NAFLD and iron overload have more severe liver disease, whereas Younossi *et al.*<sup>[19]</sup> and Angulo *et al.*<sup>[20]</sup> did not observe any relationship between iron and clinical or pathological outcomes in patients with NAFLD. Mendler *et al.*<sup>[23]</sup> have reported that patients with NAFLD have no more iron overload than patients with isolated steatosis, and that the *HFE* genotype does not influence liver damage, although unexplained hepatic iron overload is nearly always associated with metabolic abnormalities.

We analyzed in a cross-sectional study a cohort of non-obese, non-alcoholic patients with compensated chronic liver disease characterized by elevated serum ferritin levels, of varying etiology, excluding HH, to reassess the link between hyperferritinemia and other markers of the metabolic syndrome, mainly steatosis.

## MATERIALS AND METHODS

### Patients

We studied all patients consecutively referred to our Gastroenterology & Hepatology Unit, a tertiary referral center, between January 2001 and January 2004. Patients were included in the study if they had abnormal liver function tests and a high serum ferritin level, and if their clinical workup conclusively excluded a final diagnosis of HH. HH was excluded by measurement of transferrin saturation following an overnight fast, according to American Association for the Study of Liver Diseases practice guidelines<sup>[24]</sup>.

Serum ferritin was considered raised according to the WHO criteria if > 300 ng/mL in men and > 200 ng/mL in women. Patients were excluded if they had a history

of alcohol abuse (alcohol consumption > 30 g/d in men and > 20 g/d in women), obesity [body mass index (BMI)  $\geq$  30], transferrin saturation > 45%, hepatitis B surface antigen positivity, autoimmune hepatitis, celiac disease, Wilson disease,  $\alpha$ -1-antitripsin deficiency, porphyria cutanea tarda, or previous antiviral treatment in patients with chronic HCV infection. Alcohol intake and drug use or abuse was evaluated through the administration of a questionnaire. Concomitant inflammatory diseases potentially capable of causing hyperferritinemia were ruled out on the basis of the absence of clinical signs or abnormal blood test results (erythrocyte sedimentation rate, rheumatoid factor, and C reactive protein).

One hundred and twenty-four consecutive patients fitting the above criteria were selected from about 1800 subjects admitted for evaluation of abnormal LFTs to our unit (2001-2004). Clinical features, biochemical data, HCV and HBV status, histological features and iron status parameters were registered at baseline. All patients were genetically tested for *HFE* gene mutations. IR was determined by the homeostasis model assessment (HOMA) method using the following equation: insulin resistance (HOMA-IR) = fasting insulin ( $\mu$ U/mL)  $\times$  fasting glucose (mmol/L)/22.5.

All patients had liver ultrasound (US); liver biopsy was performed only when clinically appropriate and in patients who did not refuse. Steatosis on US was assessed as present or absent; when present, it was graded as mild, moderate or severe by two experienced ultrasonographers (always the same throughout the study period), who were unaware of the clinical and laboratory results. The presence of steatosis was determined in a qualitative manner according to standardized criteria<sup>[25]</sup>.

### *HFE* mutation analysis

*HFE* gene mutations were evaluated by a reverse hybridization assay (Nuclear Laser Diagnostics) that assessed 11 *HFE* gene mutations: V53M, V59M, H63D, H63H, SC65C, C282Y, Q127H, E168Q, E168X, W169X, Q283P on DNA from peripheral blood mononuclear cells. Extracted DNA fragments were amplified by PCR and PCR products were hybridized with allele-specific oligonucleotide probes, and the hybridized probes were read by a colorimetric reaction.

### Histological examination

Biopsies were evaluated for grade and stage according to Ishak<sup>[26]</sup> and, on Perl's Prussian-blue-stained sections, for iron content. Stainable iron was scored as: grade 0, no detectable iron; grade 1, granules of iron visible at 400  $\times$  magnification; grade 2, discrete iron granules visible at 100  $\times$  magnification; grade 3, iron visible at 25  $\times$  magnification, and grade 4, masses of iron visible at 10  $\times$  magnification.

### Statistics analysis

Continuous variables were summarized as mean  $\pm$  SD and categorical variables as frequency and percentage. Multiple logistic and linear regression models were used to assess the relationship of steatosis, high ferritin

**Table 1** Demographic, laboratory and histological features of 124 patients (mean  $\pm$  SD)

Variable	
Mean age (yr)	53.3 $\pm$ 1.2
Age (yr), <i>n</i> (%)	
$\leq$ 50	51 (41.2)
> 50	73 (58.8)
Sex, <i>n</i> (%)	
Male	90 (72.5)
Female	34 (27.5)
BMI (kg/m <sup>2</sup> )	
< 25	74 (59.6)
25-29.9	50 (40.3)
ALT-UNL	3.0 $\pm$ 1.0
AST-UNL	2.0 $\pm$ 1.0
GGT-UNL	2.0 $\pm$ 0.3
Ferritin (ng/mL)	799.7 $\pm$ 75.6
Serum iron ( $\mu$ g/dL)	126 $\pm$ 6.3
Platelet count $\times 10^3$ /cmm	186 $\pm$ 74.33
HOMA score	3.48 $\pm$ 1.80
Steatosis	92 (74.2)
Etiology	
Anti-HCV	53 (42.7)
NAFLD	35 (28.2)
NAFLD/diabetes	11 (8.8)
NASH	11 (8.8)
Cryptogenic	14 (11.3)
Histology (54)	
Chronic hepatitis C	27 (50)
Cirrhosis cryptogenic	9 (16.6)
NAFLD	7 (12.9)
NASH	11 (20.3)
HFE mutations	53 (42.7)
H63D heterozygous	49 (39.5)
C282Y heterozygous	2 (1.6)
C282Y/H63D compound het	2 (1.6)

ULN: Upper limit of normal.

and chronic liver disease. The dependent variable was steatosis on US, coded as 0 (absent) or 1 (present). As candidate risk factors for steatosis, we selected age, sex, BMI, presence of cirrhosis, baseline alanine aminotransferase (ALT)/aspartate aminotransferase (AST), platelets, GGT, ferritin, serum iron, transferrin, transferrin saturation, glucose, bilirubin, and diabetes. Multiple logistic regression analysis was performed to identify independent predictors of steatosis. Multiple linear regression analysis was performed to identify independent predictors of ferritin levels as a continuous dependent variable. Variables found to be associated with the dependent variables on univariate logistic or linear regression at  $P \leq 0.10$  were included in multivariate regression models. Regression analyses were performed using PROC LOGISTIC and PROC REG subroutines (SAS Institute, Inc., Cary, NC, USA)<sup>[23]</sup>.

## RESULTS

Features of the patients included in the study are shown in Table 1. The 124 patients (34 women and 90 men) had a mean age of 53.3  $\pm$  1.2 years. The mean value of ferritin was 799  $\pm$  75 ng/mL and that of serum iron was 126  $\pm$  6.3  $\mu$ g/dL.

**Table 2** Univariate analysis of risk factors for absent/present liver steatosis in 124 patients with high serum level ferritin

Variable	Steatosis		<i>P</i> value
	Absent ( <i>n</i> = 32)	Present ( <i>n</i> = 92)	
Age (yr)	50.9 $\pm$ 3.1	54.2 $\pm$ 1.3	0.06
Sex	18 (56.2)	72 (78.2)	0.14
BMI (kg/m <sup>2</sup> )	24.4 $\pm$ 3.2	25.2 $\pm$ 3.1	0.30
ALT-UNL	47.7 $\pm$ 7.7	117.5 $\pm$ 11.2	0.1
AST-UNL	35.7 $\pm$ 5.3	89 $\pm$ 10.8	0.3
GGT	93.1 $\pm$ 20.7	174.1 $\pm$ 19.7	0.03
Anti-HCV positivity	24 (75)	28 (30.4)	0.02
Ferritin (ng/mL)	464 $\pm$ 183	1060.8 $\pm$ 79	0.0006
Serum Iron ( $\mu$ g/dL)	96.3 $\pm$ 7.5	137 $\pm$ 7.7	0.8
Platelet count $\times 10^3$ /cmm	217.8 $\pm$ 16.1	176.9 $\pm$ 8.26	0.24
HOMA	3.0 $\pm$ 2.25	3.5 $\pm$ 2.8	0.23
HFE mutations	14 (43.7)	40 (43.4)	0.63
Diabetes	11 (34.3)	11 (12)	0.2

HCV infection was detected in 53 patients (42.7%), 35 of whom (28.2%) had NAFLD without overt diabetes, 11 (8.8%) had NAFLD associated with diabetes, and 11 had NASH at histology. Finally, 14 patients (11.3%) were classified as having cryptogenic chronic hepatitis.

Overall, 92 patients (74.2%) had steatosis on US: 46 moderate and 46 severe. The etiological pattern of the patients with steatosis was as follows: 35 (38%) subjects were infected with HCV, 35 (38%) had NAFLD, 11 (12%) were diabetic with NAFLD, and 11 (12%) had a diagnosis of NASH at histology.

HCV infection was detected in 53 patients (42.7%). All these were infected by HCV genotype 1b; 36 (68%) had steatosis, nine were detected by US and 27 by liver biopsy.


At liver biopsy, performed in 54 patients out of 124 (43.5%), 27 (50%) had chronic hepatitis C and nine (16.6%) had micronodular cryptogenic cirrhosis. Seven patients (12.9%) had NAFLD (macrovesicular steatosis) and 11 (20.3%), NASH (macrovesicular steatosis and lobular inflammation). Seventeen patients (31.5%) had siderosis: eight, grade 1 and nine, grade 2.

Among the 11 HFE gene mutations analyzed, only two (H63D and C282Y) were present in our population, while the remaining nine mutations were not found in any patient. H63D and C282Y mutations were distributed as follows: 53 patients tested (42.7%) carried at least one HFE gene mutation. These were distributed as follows: 49 (39.5%) patients were H63D heterozygous, two (1.6%) were C282Y heterozygous, and two (1.6%) were C282Y/H63D, compound heterozygous. None were ultimately diagnosed with HH on clinical and laboratory criteria.


Univariate and multivariate analyses were performed to identify predictors of steatosis. By univariate analysis age ( $P = 0.06$ ), ferritin ( $P = 0.0006$ ), GGT ( $P = 0.03$ ) and anti-HCV positivity ( $P = 0.02$ ) were associated with steatosis ( $P < 0.10$ ) (Table 2). By multivariate analysis, ferritin (OR: 1.002; 95% CI: 1.001-1.004), and GGT (OR: 1.007; 95% CI: 1.001-1.013) were the only independent predictors of steatosis (Table 3). The baseline ferritin

**Table 3** Predictors of steatosis in 124 patients by logistic regression model

Predictor	Univariate analysis		Multivariate analysis	
	OR (95% CI)	P value	OR (95% CI)	P value
Age (yr)	0.962 (0.923-1.002)	0.060	0.97 (0.94-1.14)	0.23
Sex	0.455 (0.160-1.297)	0.14	-	-
BMI (kg/m <sup>2</sup> )	1.050 (0.96-1.14)	0.23	-	-
ALT-UNL	0.997 (0.993-1.001)	0.12	-	-
AST-UNL	0.998 (0.994-1.002)	0.36	-	-
GGT-UNL	1.007 (1.001-1.013)	0.030	1.007 (1.003-1.014)	0.0043
Anti-HCV positivity	0.274 (0.110-0.682)	0.005	0.40 (0.20-1.10)	0.08
Platelet count × 10 <sup>3</sup> /cmm	1.000 (1.000-1.000)	0.24	-	-
Ferritin (ng/mL)	1.002 (1.001-1.004)	0.0006	1.003 (1.002-1.004)	0.0009
Serum Iron (µg/dL)	0.999 (0.991-1.008)	0.84	-	-
HFE mutations	0.796 (0.313-2.020)	0.63	-	-
Diabetes	0.995 (0.986-1.004)	0.28	-	-



**Figure 1** Baseline GGT levels according to steatosis in 124 non-obese, non-alcoholic patients without hereditary haemochromatosis (HH).



**Figure 2** Baseline ferritin levels according to steatosis and HCV infection status in 124 non-obese, non-alcoholic patients without hereditary haemochromatosis (HH).

and GGT levels in patients with or without steatosis are shown in Figures 1 and 2.

To identify predictors of ferritin levels, univariate and multivariate linear regression analyses were performed. Univariate analysis showed that male sex, anti-HCV positivity, platelet count, AST, ALT, GGT level and steatosis were significantly associated with ferritin levels. The model for the independent predictors of ferritin levels as a continuous variable by multiple linear regression analysis (Table 4) included anti-HCV

**Table 4** Multivariate analysis of risk factors for high serum ferritin levels in 124 patients by linear regression model

Variable	β	SE	P
Male	93.183	183.13	0.612
ALT-UNL	-0.07174	1.09734	0.948
AST-UNL	1.06027	1.05841	0.319
GGT-UNL	0.92457	0.5746	0.111
Anti-HCV positivity	521.964	169.40	0.0028
Platelet count × 10 <sup>3</sup> /cmm	-0.00250	0.0010	0.0161
Steatosis	933.7287	180.437	< 0.0001

positivity ( $P = 0.0028$ ), platelet count ( $P = 0.0161$ ) and steatosis ( $P < 0.0001$ ). Figure 2 outlines baseline ferritin levels according to HCV infection status.

## DISCUSSION

Hyperferritinemia is frequent in patients with chronic liver disease, whatever the etiology of the underlying damage. In this cohort of 124 non-obese, non-alcoholic patients with high serum ferritin levels, without HH, the cause of liver disease was chronic HCV infection in 42.7%, NAFLD/NASH in 45.9%, and untraceable in 11%. Steatosis on US was predicted independently by ferritin and GGT levels. High ferritin levels were associated with HCV infection and with more advanced liver disease, shown by low platelet counts.

In our study, no patients could be finally diagnosed with HH, although at least one of the characterized *HFE* gene mutations (C282Y and/or H63D, mostly the latter) was found in 50% of our patients in an heterozygote state. In fact, none of these carriers of *HFE* mutations had a transferrin saturation > 45%, liver siderosis beyond grade 1, or evidence of any other organ damage attributable to iron overload. It is noteworthy that an excess H63D allele frequency observed in our patients, as compared to the 12%-19% range observed in the normal population in our area<sup>[5,28]</sup>, suggests that heterozygosity for this mutated allele may increase the appearance of high ferritin levels, once predisposing factors such as IR, steatosis and cirrhosis are operating.

Chronic hepatitis C, with or without cirrhosis, often presents with abnormal iron indices<sup>[29,30]</sup>, particularly

with raised levels of ferritin, which does not necessarily represents iron overload. Several mechanisms have been hypothesized to explain the altered iron indices and possible liver siderosis, including an excess of oxygen free radicals, increased fibrogenesis through activation of stellate cells and impairment of the host immune response<sup>[31-34]</sup>. Among our 29 patients with chronic liver disease caused by HCV genotype 1b, in whom liver biopsy was performed, only 17 had siderosis (eight mild, nine moderate, none severe). Theoretically, serum ferritin could be elevated as an acute phase reaction linked to the necroinflammatory process of chronic hepatitis C, but the moderate increase in ALT and the degree of activity typically observed in these patients negates this interpretation, even if in our analysis chronic HCV infection was independently linked to higher ferritin levels at multivariate analysis. It is however difficult to disentangle the role of HCV from that of steatosis, which is commonly associated with raised levels of ferritin<sup>[35,36]</sup>, and is a common finding in HCV infection<sup>[37]</sup>, even when caused by HCV genotype 1<sup>[14]</sup>. In our study, HCV-infected patients also showed a moderate degree of steatosis. NAFLD is known to be by itself strongly associated with the metabolic syndrome, which may explain the strong relationship between HCV infection and diabetes. The association between IR and moderate/severe steatosis in chronic hepatitis C is well supported<sup>[36-38]</sup>. In fact, IR could lead to the development of steatosis of the liver in HCV-infected patients<sup>[14]</sup>, which makes them prone to the onset of diabetes.

In NAFLD, lipid peroxidation promotes transition from steatosis to steatohepatitis, which involves multiple cellular adaptations and evokes biomarkers of the oxidative stress that occurs when fatty acid metabolism is altered. The induction of heme-oxygenase 1 is an adaptive response against oxidative damage elicited by lipid peroxidation, and may be critical in the progression of the disease<sup>[39]</sup>. The association we found between ferritin and moderate/severe steatosis supports the concept that serum ferritin is a risk factor for fatty liver. Further support for this hypothesis is lent by the data of Zelber-Sagi *et al*<sup>[40]</sup> who demonstrated that NAFLD is the major determinant of increased serum ferritin levels at a population-based level. Moreover, they have shown that the association between serum ferritin and insulin is much more evident in the NAFLD group. Although recent studies have suggested that serum ferritin is a marker of IR<sup>[42-44]</sup>, we could not provide evidence for a direct correlation between IR and elevated levels of serum ferritin. Consonant with Zelber-Sagi *et al*<sup>[40]</sup>, we believe that the association found in previous studies between ferritin and IR may depend upon undiagnosed NAFLD.

Data from the third National Health and Nutrition Examination Survey (1988-1994) show a significant association between elevated serum ferritin and newly diagnosed diabetes mellitus<sup>[16]</sup>. We found that 17.7% of our patients had type 2 diabetes. In our study, however, ferritin levels were not significantly associated with IR,

as evaluated by HOMA score, as well as by the presence of overt diabetes, probably as a result of the relatively small size of this sample, in which younger patients under evaluation for chronic hepatitis C predominated. Although a recent study has suggested that diabetes is the main factor accounting for the high ferritin level detected in chronic HCV infection<sup>[45]</sup>, we could not provide evidence for a direct correlation between IR and hyperferritinemia.

An important finding of this work is the association we found between raised ferritin and reduction in platelet counts, a known marker of portal hypertension<sup>[46]</sup>. We confirmed the observation by Bugianesi *et al*<sup>[36]</sup> who demonstrated that serum ferritin, but not iron stores, was a significant predictor of severe fibrosis in patients with NAFLD. All these data provide further evidence that hyperferritinemia might be another surrogate marker of advanced liver disease of any etiology.

According to recent reports, GGT is an independent predictor of liver steatosis<sup>[14]</sup>. Our data indicate that patients with elevated GGT levels have the greatest likelihood of having moderate/severe steatosis. The administration of a questionnaire regarding alcohol intake and drug use or abuse makes us confident in excluding any role of these potential confounders on GGT levels. Lack of data on smoking, however, could affect the accuracy of the results<sup>[47]</sup>. The association between GGT levels and steatosis is likely the result of the association between regional body fat distribution and fatty liver, irrespective of total body fat quantity, which is consistent with the assumption that GGT is a surrogate marker of central fat accumulation. Therefore, the GGT level may be a simple and reliable marker of visceral and hepatic fat and, by inference, of hepatic IR. Thus, patients with elevated serum ferritin and GGT levels are at risk of developing liver steatosis<sup>[48]</sup>. Modelling the indication for US scanning on these predictors would maximize its cost effectiveness.

The main limitation of the current study, as well as of other cross-sectional studies, is that it is unable to distinguish the temporality of the associations between hyperferritinemia, steatosis and chronic hepatitis C. Lack of histological data in a proportion of subjects, particularly on intra-hepatic iron deposition, could also affect the interpretation of our findings. We are aware that the use of a more sensitive imaging technique such as magnetic resonance imaging could improve the rate of steatosis detection. In addition, we cannot exclude the possibility that denied alcohol abuse may be responsible for the observed prevalence of steatosis. A further methodological issue arises in the potential limitation of the generalizability of our results to new populations and settings. Our study included a Mediterranean cohort of non-obese patients without HH, which limits the broad application of the results.

In conclusion, this study shows that in a non-obese cohort of non alcoholic patients, steatosis and chronic HCV infection are the main causes of hyperferritinemia. In Southern European populations, the finding of high

ferritin levels, after the exclusion of diagnosis of HH, represents a risk factor for steatosis and has clinical relevance, being associated with low platelet count.

## ACKNOWLEDGMENTS

The authors thank Warren Blumberg for his forbearance in editing the manuscript.

## COMMENTS

### Background

Patients with chronic hepatitis C virus (HCV) infection often have elevated serum iron indices, but these do not accurately reflect hepatic iron content, nor are they able to predict clinically important endpoints, such as progression of fibrosis and responsiveness to interferon-based regimens.

### Research frontiers

In this study, the authors showed that, in a non-obese cohort of non-alcoholic patients, steatosis and chronic HCV infection are the main causes of hyperferritinemia. In southern European populations, high ferritin levels, after exclusion of a diagnosis of hereditary hemochromatosis (HH), represent a risk factor for steatosis and have clinical relevance, being associated with low platelet count.

### Innovations and breakthroughs

In a non-obese cohort of non-alcoholic patients with chronically abnormal liver function tests, without HH, serum ferritin high level is, therefore, a risk factor for steatosis.

### Applications

Hyperferritinemia can be used as markers of steatosis in non-obese and non-alcoholic patients.

### Peer review

The authors study the underlying liver disease in a cohort of individuals selected because they had both chronic liver disease as well as elevated serum ferritin levels. They found that most individuals had either chronic HCV or fatty liver disease. Additional analysis of clinicopathological data showed an association between ferritin and steatosis and GGT and steatosis. Overall the paper is well written.

## REFERENCES

- 1 **Le Page L**, Leflon P, Mahévas M, Duhaut P, Smail A, Salle V, Cevallos R, Ducroix JP. [Aetiological spectrum of hyperferritinemia] *Rev Med Interne* 2005; **26**: 368-373
- 2 **Lee MH**, Means RT Jr. Extremely elevated serum ferritin levels in a university hospital: associated diseases and clinical significance. *Am J Med* 1995; **98**: 566-571
- 3 **Feder JN**, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R Jr, Ellis MC, Fullan A, Hinton LM, Jones NL, Kimmel BE, Kronmal GS, Lauer P, Lee VK, Loeb DB, Mapa FA, McClelland E, Meyer NC, Mintier GA, Moeller N, Moore T, Morikang E, Prass CE, Quintana L, Starnes SM, Schatzman RC, Brunke KJ, Drayna DT, Risch NJ, Bacon BR, Wolff RK. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. *Nat Genet* 1996; **13**: 399-408
- 4 **Beutler E**, Gelbart T, West C, Lee P, Adams M, Blackstone R, Pockros P, Kosty M, Venditti CP, Phatak PD, Seese NK, Chorney KA, Ten Elshof AE, Gerhard GS, Chorney M. Mutation analysis in hereditary hemochromatosis. *Blood Cells Mol Dis* 1996; **22**: 187-194; discussion 194a-194b
- 5 **Candore G**, Mantovani V, Balistreri CR, Lio D, Colonna-Romano G, Cerreta V, Carru C, Deiana L, Pes G, Menardi G, Perotti L, Miotti V, Bevilacqua E, Amoroso A, Caruso C. Frequency of the HFE gene mutations in five Italian populations. *Blood Cells Mol Dis* 2002; **29**: 267-273
- 6 **Marchesini G**, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. *Diabetes* 2001; **50**: 1844-1850
- 7 **Bonkovsky HL**, Banner BF, Rothman AL. Iron and chronic viral hepatitis. *Hepatology* 1997; **25**: 759-768
- 8 **Sebastiani G**, Vario A, Ferrari A, Pistis R, Noventa F, Alberti A. Hepatic iron, liver steatosis and viral genotypes in patients with chronic hepatitis C. *J Viral Hepat* 2006; **13**: 199-205
- 9 **Van Thiel DH**, Friedlander L, Fagiuolo S, Wright HI, Irish W, Gavalier JS. Response to interferon alpha therapy is influenced by the iron content of the liver. *J Hepatol* 1994; **20**: 410-415
- 10 **Olynyk JK**, Reddy KR, Di Bisceglie AM, Jeffers LJ, Parker TI, Radick JL, Schiff ER, Bacon BR. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. *Gastroenterology* 1995; **108**: 1104-1109
- 11 **D'Souza RF**, Feakins R, Mears L, Sabin CA, Foster GR. Relationship between serum ferritin, hepatic iron staining, diabetes mellitus and fibrosis progression in patients with chronic hepatitis C. *Aliment Pharmacol Ther* 2005; **21**: 519-524
- 12 **Lonardo A**, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. *Gastroenterology* 2004; **126**: 586-597
- 13 **Adinolfi LE**, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. *Hepatology* 2001; **33**: 1358-1364
- 14 **Cammà C**, Bruno S, Di Marco V, Di Bona D, Rumi M, Vinci M, Rebucci C, Cividini A, Pizzolanti G, Minola E, Mondelli MU, Colombo M, Pinzello G, Craxi A. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. *Hepatology* 2006; **43**: 64-71
- 15 **Hwang SJ**, Luo JC, Chu CW, Lai CR, Lu CL, Tsay SH, Wu JC, Chang FY, Lee SD. Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. *J Gastroenterol Hepatol* 2001; **16**: 190-195
- 16 **Ford ES**, Cogswell ME. Diabetes and serum ferritin concentration among U.S. adults. *Diabetes Care* 1999; **22**: 1978-1983
- 17 **Paris R**. Association of hepatitis C and diabetes mellitus. *Ann Intern Med* 2001; **135**: 141-142
- 18 **James OF**, Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. *J Hepatol* 1998; **29**: 495-501
- 19 **Younossi ZM**, Gramlich T, Bacon BR, Matteoni CA, Boparai N, O'Neill R, McCullough AJ. Hepatic iron and nonalcoholic fatty liver disease. *Hepatology* 1999; **30**: 847-850
- 20 **Angulo P**, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. *Hepatology* 1999; **30**: 1356-1362
- 21 **George DK**, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, Jazwinska EC, Powell LW. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. *Gastroenterology* 1998; **114**: 311-318
- 22 **Bonkovsky HL**, Jawaid Q, Tortorelli K, LeClair P, Cobb J, Lambrecht RW, Banner BF. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. *J Hepatol* 1999; **31**: 421-429
- 23 **Mendler MH**, Turlin B, Moirand R, Jouanolle AM, Sapey T, Guyader D, Le Gall JY, Brissot P, David V, Deugnier Y. Insulin resistance-associated hepatic iron overload. *Gastroenterology* 1999; **117**: 1155-1163
- 24 **Tavill AS**. Diagnosis and management of hemochromatosis. *Hepatology* 2001; **33**: 1321-1328
- 25 **Siegelman ES**, Rosen MA. Imaging of hepatic steatosis. *Semin Liver Dis* 2001; **21**: 71-80
- 26 **Ishak KG**. Chronic hepatitis: morphology and nomenclature. *Mod Pathol* 1994; **7**: 690-713

- 27 SAS Technical Report, SAS/STAS software: Changes & enhancement, release 6.07. North Carolina: SAS Institute Inc, 1992
- 28 **Campo S**, Restuccia T, Villari D, Raffa G, Cucinotta D, Squadrito G, Pollicino T, Raimondo G. Analysis of haemochromatosis gene mutations in a population from the Mediterranean Basin. *Liver* 2001; **21**: 233-236
- 29 **Arber N**, Konikoff FM, Moshkowitz M, Baratz M, Hallak A, Santo M, Halpern Z, Weiss H, Gilat T. Increased serum iron and iron saturation without liver iron accumulation distinguish chronic hepatitis C from other chronic liver diseases. *Dig Dis Sci* 1994; **39**: 2656-2659
- 30 **Riggio O**, Montagnese F, Fiore P, Folino S, Giambartolomei S, Gandin C, Merli M, Quinti I, Violante N, Caroli S, Senofonte O, Capocaccia L. Iron overload in patients with chronic viral hepatitis: how common is it? *Am J Gastroenterol* 1997; **92**: 1298-1301
- 31 **Olynyk JK**, Clarke SL. Iron overload impairs pro-inflammatory cytokine responses by Kupffer cells. *J Gastroenterol Hepatol* 2001; **16**: 438-444
- 32 **Weiss G**. Iron and immunity: a double-edged sword. *Eur J Clin Invest* 2002; **32** Suppl 1: 70-78
- 33 **Rigamonti C**, Andorno S, Maduli E, Morelli S, Pittau S, Nicosia G, Boldorini R, Sartori M. Iron, hepatic stellate cells and fibrosis in chronic hepatitis C. *Eur J Clin Invest* 2002; **32** Suppl 1: 28-35
- 34 **Martinelli AL**, Ramalho LN, Zucoloto S. Hepatic stellate cells in hepatitis C patients: relationship with liver iron deposits and severity of liver disease. *J Gastroenterol Hepatol* 2004; **19**: 91-98
- 35 **Fargion S**, Mattioli M, Fracanzani AL, Sampietro M, Tavazzi D, Fociani P, Taioli E, Valenti L, Fiorelli G. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. *Am J Gastroenterol* 2001; **96**: 2448-2455
- 36 **Bugianesi E**, Manzini P, D'Antico S, Vanni E, Longo F, Leone N, Massarenti P, Piga A, Marchesini G, Rizzetto M. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. *Hepatology* 2004; **39**: 179-187
- 37 **Lonardo A**, Loria P, Adinolfi LE, Carulli N, Ruggiero G. Hepatitis C and steatosis: a reappraisal. *J Viral Hepat* 2006; **13**: 73-80
- 38 **Rubbia-Brandt L**, Fabris P, Paganin S, Leandro G, Male PJ, Giostra E, Carlotto A, Bozzola L, Smedile A, Negro F. Steatosis affects chronic hepatitis C progression in a genotype specific way. *Gut* 2004; **53**: 406-412
- 39 **Malaguarnera L**, Madeddu R, Palio E, Arena N, Malaguarnera M. Heme oxygenase-1 levels and oxidative stress-related parameters in non-alcoholic fatty liver disease patients. *J Hepatol* 2005; **42**: 585-591
- 40 **Zelber-Sagi S**, Nitzan-Kaluski D, Halpern Z, Oren R. NAFLD and hyperinsulinemia are major determinants of serum ferritin levels. *J Hepatol* 2007; **46**: 700-707
- 41 **Trombini P**, Piperno A. Ferritin, metabolic syndrome and NAFLD: elective attractions and dangerous liaisons. *J Hepatol* 2007; **46**: 549-552
- 42 **Fernández-Real JM**, Ricart-Engel W, Arroyo E, Balançá R, Casamitjana-Abella R, Cabrero D, Fernández-Castañer M, Soler J. Serum ferritin as a component of the insulin resistance syndrome. *Diabetes Care* 1998; **21**: 62-68
- 43 **Tuomainen TP**, Nyyssönen K, Salonen R, Tervahauta A, Korpela H, Lakka T, Kaplan GA, Salonen JT. Body iron stores are associated with serum insulin and blood glucose concentrations. Population study in 1,013 eastern Finnish men. *Diabetes Care* 1997; **20**: 426-428
- 44 **Jiang R**, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. *JAMA* 2004; **291**: 711-717
- 45 **Lecube A**, Hernández C, Genescà J, Esteban JI, Jardí R, García L, Simó R. Diabetes is the main factor accounting for the high ferritin levels detected in chronic hepatitis C virus infection. *Diabetes Care* 2004; **27**: 2669-2675
- 46 **Pagliari L**, D'Amico G, Luca A, Pasta L, Politi F, Aragona E, Malizia G. Portal hypertension: diagnosis and treatment. *J Hepatol* 1995; **23** Suppl 1: 36-44
- 47 **Stranges S**, Dorn JM, Muti P, Freudenheim JL, Farinaro E, Russell M, Nochajski TH, Trevisan M. Body fat distribution, relative weight, and liver enzyme levels: a population-based study. *Hepatology* 2004; **39**: 754-763
- 48 **Hourigan LF**, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, Powell EE. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. *Hepatology* 1999; **29**: 1215-1219

S- Editor Tian L L- Editor Kerr C E- Editor Zheng XM